All posts
-
Press Releases — October 19, 2023
C2i Genomics and OncoDNA Begin Molecular Residual Disease Testing Across Europe
-
Press Releases — October 18, 2023
C2i Genomics and Gustave Roussy Collaborate to Demonstrate Utility of ctDNA-guided Immunotherapy in Early-Stage Solid Tumors
-
Press Coverage — August 31, 2023
C2i Genomics: Building A Comprehensive Whole-Genome Cancer Monitoring Platform
-
Press Coverage — August 20, 2023
AI cancer startup collaborates with top Israeli hospital
-
Press Coverage — August 11, 2023
C2i Genomics and Ichilov bring cancer detection and monitoring platform to Israel
-
Press Releases — August 10, 2023
C2i Genomics and Ichilov Join Forces to Bring Cancer Detection and Monitoring Platform to Israel
-
Press Coverage — June 21, 2023
C2i Genomics’ Cutting-Edge Blood Tests Transform Cancer Diagnosis and Monitoring
-
Press Coverage — June 3, 2023
ASCO: C2i Genomics CEO, CTO aim to create a ‘one-stop shop for precision oncology’
-
Press Coverage — May 31, 2023
How C2i Genomics builds on AWS to transform cancer care
-
Press Coverage — April 20, 2023
C2i Genomics Expands Data on Whole-Genome Sequencing MRD Test in Colon, Lung Cancer